Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.
This meeting is being supported by Instrumentation Laboratory
Trainees and fellows interested in learning about the new and upcoming treatments for hemophilia
At the conclusion of this activity, I will be able to:
- Understand the rationale for experimental therapies and the untested assumptions that are likely to influence the degree of success.
- Gain knowledge of the preclinical rationale and the early clinical data for experimental therapies that are in trials.
Peter Collins - "Clinical trials of enhanced half-life FVIII and FIX"
Gary Gilbert - "Experimental therapies"
|Geoffrey Barnes, MD||Portola||Consulting|
|Blue Cross Blue Shield of Michigan||Research|
|Chris Ward, PhD||Bayer||Speaker|
|Boehringer-Ingelheim||Speaker, Advisory Board|
|BMS/Pfizer||Speaker, Advisory Board|
|Gary Gilbert||Baxalta||Advisory Board|
|Harvard Med School/VA Healthcare||Inventor|
|Peter Collins||Novo Nordisk||Consultant|
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.